We are live on ! Find out more
RBC

Roble Belko & Company Portfolio holdings

AUM $925M
1-Year Est. Return 19.7%
This Fund
S&P 500
This Quarter Est. Return
+0.84%
1 Year Est. Return
+19.7%
3 Year Est. Return
+53.27%
5 Year Est. Return
+47.85%
10 Year Est. Return
+149.75%
AUM
$263M
AUM Growth
+$5.04M
Cap. Flow
+$2.74M
Cap. Flow %
1.04%
Top 10 Hldgs %
61.93%
Holding
345
New
7
Increased
22
Reduced
62
Closed
12
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BAF
151
DELISTED
BLACKROCK MUNICIPAL INCOME INVESTMENT QUALITY TRUST
BAF
$24K 0.01%
1,732
ESRX
152
DELISTED
Express Scripts Holding Company
ESRX
$24K 0.01%
311
-85
-21% -$6.38K
ABBV icon
153
AbbVie
ABBV
$466B
$23K 0.01%
243
HWM icon
154
Howmet Aerospace
HWM
$91.6B
$23K 0.01%
1,790
-1,328
-43% -$19.7K
VGT icon
155
Vanguard Information Technology ETF
VGT
$150B
$23K 0.01%
1,000
WY icon
156
Weyerhaeuser
WY
$15.3B
$23K 0.01%
620
-770
-55% -$28.2K
SAVE
157
DELISTED
Spirit Airlines, Inc.
SAVE
$23K 0.01%
630
BPK
158
DELISTED
Blackrock Muni 2018 Term Tr
BPK
$23K 0.01%
1,554
BURL icon
159
Burlington
BURL
$14.9B
$22K 0.01%
143
ETN icon
160
Eaton
ETN
$165B
$22K 0.01%
300
TXN icon
161
Texas Instruments
TXN
$244B
$22K 0.01%
204
CTSH icon
162
Cognizant
CTSH
$27B
$21K 0.01%
270
GLD icon
163
SPDR Gold Trust
GLD
$148B
$21K 0.01%
176
+4
+2% +$495
BOE icon
164
BlackRock Enhanced Global Dividend Trust
BOE
$678M
$20K 0.01%
1,820
HBAN icon
165
Huntington Bancshares
HBAN
$32.1B
$20K 0.01%
1,355
HDV
166
iShares Core High Dividend ETF
HDV
$15.2B
$20K 0.01%
1,190
VFH icon
167
Vanguard Financials ETF
VFH
$13.1B
$20K 0.01%
294
+72
+32% +$5.03K
BMRN icon
168
BioMarin Pharmaceuticals
BMRN
$12.4B
$19K 0.01%
205
-633
-76% -$55.4K
CVS icon
169
CVS Health
CVS
$114B
$19K 0.01%
300
EEFT icon
170
Euronet Worldwide
EEFT
$2.47B
$19K 0.01%
231
MCHP icon
171
Microchip Technology
MCHP
$39.8B
$19K 0.01%
408
AZN icon
172
AstraZeneca
AZN
$258B
$18K 0.01%
260
SEE
173
DELISTED
Sealed Air
SEE
$18K 0.01%
415
-795
-66% -$34.9K
BIIB icon
174
Biogen
BIIB
$31.8B
$17K 0.01%
60
-1,236
-95% -$347K
BMY icon
175
Bristol-Myers Squibb
BMY
$129B
$17K 0.01%
310
-538
-63% -$29.1K

Similar funds

Roble Belko & Company's Q2 2018 Portfolio in Review

As of Q2 2018, Roble Belko & Company held 345 positions worth $263M, up 2% from $257M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Roble Belko & Company's Q2 2018 filing shows 7 new, 22 increased, 62 reduced and 12 closed positions. Its largest new stake was Vanguard Short-Term Inflation-Protected Securities Index Fund: 221,950 shares worth $10.8M. The largest sale was iShares North American Natural Resources ETF, an estimated $7.18M.

By sector, the portfolio is most concentrated in Miscellaneous at 95% of assets, up from 95% a quarter earlier, followed by Real Estate and Technology.

  • Roble Belko & Company's largest Q2 2018 buy was Vanguard Short-Term Inflation-Protected Securities Index Fund: 221,950 shares worth $10.8M.
  • Roble Belko & Company added most to Vanguard Total International Stock ETF in Q2 2018, an estimated $2.83M increase.
  • Roble Belko & Company's biggest Q2 2018 reduction was iShares North American Natural Resources ETF, cutting an estimated $7.18M.
  • Roble Belko & Company fully exited iShares US Energy ETF in Q2 2018, selling an estimated $133K.
  • Roble Belko & Company's ten largest holdings make up 62% of its $263M portfolio in Q2 2018.
  • Roble Belko & Company opened 7 new positions and closed 12 in Q2 2018.
  • Roble Belko & Company's portfolio value rose 2% quarter-over-quarter to $263M.

Based on Roble Belko & Company's 13F filing for Q2 2018, filed 8 Aug 2018.